NVUS - ト―カイ・ファ―マシュ―ティカルズ (Novus Therapeutics Inc.) ト―カイ・ファ―マシュ―ティカルズ

 NVUSのチャート


 NVUSの企業情報

symbol NVUS
会社名 Novus Therapeutics Inc (ト―カイ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ノーバス・セラピーティクス(Novus Therapeutics Inc.)(旧名:Tokai Pharmaceuticals Inc.)は製薬会社である。同社は主に耳、鼻、喉の製品を購入・開発・商業化する。同社は2つのプラットフォームを有する。OP-01フォームプラットフォームは耳・鼻腔・副鼻腔の治療薬の送達ビヒクルとして使用されるために開発され、現在、急性中耳炎に対する改善された治療選択肢として開発されている。OP-02界面活性剤プログラムは健康な中耳を改善・維持するように設計された毎日の鼻スプレーであり、中耳炎患者及び耳管機能不全の患者のための潜在的な治療選択肢として開発されていて、界面活性剤ジパルミトイルホスファチジルコリン及び展着剤コレステリルパルミテートという2つの成分を含む組合せ薬物製品である。同社の製品は鼻孔を通って鼻腔の後部にある耳管の開口部に向かって噴霧される。  ト―カイ・ファ―マシュ―ティカルズは、臨床段階の米国のバイオ医薬品企業。前立腺癌および他のホルモン主導の疾患の治療のための新規の独自の治療法の開発に従事する。薬剤候補「galeterone」は、選択性が高く多標的な経口小分子薬剤候補。去勢抵抗性前立腺癌を有する患者の治療に「galeterone」の当初の開発に焦点を当てる。   
本社所在地 19900 MacArthur Blvd. Suite 550 Irvine CA 92612 USA
代表者氏名 Keith A. Katkin キース・A・カトキン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 949-238-8090
設立年月日 38047
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 7人
url www.tokaipharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/nvus
adr_tso
EBITDA EBITDA(百万ドル) -11.04300
終値(lastsale) 4.15
時価総額(marketcap) 39101893.45
時価総額 時価総額(百万ドル) 38.72501
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 19.53601
当期純利益 当期純利益(百万ドル) -11.07500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novus Therapeutics Inc revenues was not reported. Net loss decreased 25% to $6M. Lower net loss reflects General and administrative decrease of 49% to $3.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.03 to -$0.70.

 NVUSのテクニカル分析


 NVUSのニュース

   Novus Therapeutics Appoints June Lee, M.D., to Board of Directors  2020/12/09 13:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company’s Board of Directors.
   Israel Gp Ltd. Orbimed Sells 103,200 Shares of Novus Therapeutics, Inc. (NASDAQ:NVUS) Stock  2020/12/06 09:46:49 Watchlist News
Novus Therapeutics, Inc. (NASDAQ:NVUS) major shareholder Israel Gp Ltd. Orbimed sold 103,200 shares of the company’s stock in a transaction dated Wednesday, December 2nd. The shares were sold at an average price of $21.60, for a total value of $2,229,120.00. The sale was disclosed in a filing with the SEC, which is available at this […]
   Zacks: Analysts Anticipate Novus Therapeutics, Inc. (NASDAQ:NVUS) to Post -$1.64 EPS  2020/11/16 17:23:30 Transcript Daily
Wall Street brokerages expect Novus Therapeutics, Inc. (NASDAQ:NVUS) to report earnings of ($1.64) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Novus Therapeutics’ earnings. Novus Therapeutics reported earnings of ($3.96) per share in the same quarter last year, which indicates a positive year over year growth rate of 58.6%. […]
   Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16  2020/11/10 22:04:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corpo
   Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis  2020/11/02 13:00:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
   Novus Therapeutics Appoints June Lee, M.D., to Board of Directors  2020/12/09 13:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company’s Board of Directors.
   Israel Gp Ltd. Orbimed Sells 103,200 Shares of Novus Therapeutics, Inc. (NASDAQ:NVUS) Stock  2020/12/06 09:46:49 Watchlist News
Novus Therapeutics, Inc. (NASDAQ:NVUS) major shareholder Israel Gp Ltd. Orbimed sold 103,200 shares of the company’s stock in a transaction dated Wednesday, December 2nd. The shares were sold at an average price of $21.60, for a total value of $2,229,120.00. The sale was disclosed in a filing with the SEC, which is available at this […]
   Zacks: Analysts Anticipate Novus Therapeutics, Inc. (NASDAQ:NVUS) to Post -$1.64 EPS  2020/11/16 17:23:30 Transcript Daily
Wall Street brokerages expect Novus Therapeutics, Inc. (NASDAQ:NVUS) to report earnings of ($1.64) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Novus Therapeutics’ earnings. Novus Therapeutics reported earnings of ($3.96) per share in the same quarter last year, which indicates a positive year over year growth rate of 58.6%. […]
   Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16  2020/11/10 22:04:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corpo
   Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis  2020/11/02 13:00:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
   Novus Therapeutics Appoints June Lee, M.D., to Board of Directors  2020/12/09 13:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company’s Board of Directors.
   Israel Gp Ltd. Orbimed Sells 103,200 Shares of Novus Therapeutics, Inc. (NASDAQ:NVUS) Stock  2020/12/06 09:46:49 Watchlist News
Novus Therapeutics, Inc. (NASDAQ:NVUS) major shareholder Israel Gp Ltd. Orbimed sold 103,200 shares of the company’s stock in a transaction dated Wednesday, December 2nd. The shares were sold at an average price of $21.60, for a total value of $2,229,120.00. The sale was disclosed in a filing with the SEC, which is available at this […]
   Zacks: Analysts Anticipate Novus Therapeutics, Inc. (NASDAQ:NVUS) to Post -$1.64 EPS  2020/11/16 17:23:30 Transcript Daily
Wall Street brokerages expect Novus Therapeutics, Inc. (NASDAQ:NVUS) to report earnings of ($1.64) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Novus Therapeutics’ earnings. Novus Therapeutics reported earnings of ($3.96) per share in the same quarter last year, which indicates a positive year over year growth rate of 58.6%. […]
   Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16  2020/11/10 22:04:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corpo
   Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis  2020/11/02 13:00:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

 関連キーワード  (医薬品 米国株 ト―カイ・ファ―マシュ―ティカルズ NVUS Novus Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)